Indaptus Therapeutics is trading 5.84% higher at $3.99 in pre-market, primarily supported by stronger biotech sentiment, with XBI up 2.61%. - Shares closed at $3.77 on September 23, 2026. - No company-specific announcement, earnings release, or regulatory catalyst was identified for September 24. - The September 8 private placement raising approximately $24 million remains background, not a fresh catalyst; the move also follows recent volatility.